Swedbank AB Buys 2,350 Shares of United Therapeutics Corporation $UTHR

Swedbank AB grew its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 0.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 327,122 shares of the biotechnology company’s stock after acquiring an additional 2,350 shares during the quarter. Swedbank AB owned about 0.75% of United Therapeutics worth $193,977,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Leuthold Group LLC lifted its stake in shares of United Therapeutics by 41.4% in the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock valued at $5,200,000 after purchasing an additional 3,126 shares during the period. UBS Group AG grew its position in United Therapeutics by 45.3% during the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock valued at $110,045,000 after buying an additional 70,445 shares during the period. Perpetual Ltd acquired a new stake in United Therapeutics during the fourth quarter valued at $1,059,000. SG Americas Securities LLC increased its holdings in United Therapeutics by 88.6% in the fourth quarter. SG Americas Securities LLC now owns 26,960 shares of the biotechnology company’s stock valued at $13,136,000 after buying an additional 12,663 shares in the last quarter. Finally, Brookstone Capital Management increased its holdings in United Therapeutics by 25.4% in the fourth quarter. Brookstone Capital Management now owns 6,622 shares of the biotechnology company’s stock valued at $3,227,000 after buying an additional 1,342 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Cantor Fitzgerald increased their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Raymond James Financial began coverage on United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target for the company. Royal Bank Of Canada reduced their price target on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Morgan Stanley set a $516.00 price target on United Therapeutics in a research report on Thursday, May 7th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Thursday, June 11th. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $619.42.

United Therapeutics Price Performance

United Therapeutics stock traded up $11.29 during midday trading on Tuesday, reaching $558.53. The company had a trading volume of 142,871 shares, compared to its average volume of 494,474. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The company has a market capitalization of $23.71 billion, a P/E ratio of 20.62, a P/E/G ratio of 1.82 and a beta of 0.58. The firm’s fifty day simple moving average is $557.83 and its 200-day simple moving average is $528.36.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s revenue was down 1.6% compared to the same quarter last year. During the same period in the previous year, the company earned $6.63 EPS. On average, analysts expect that United Therapeutics Corporation will post 26.63 EPS for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $577.18, for a total value of $5,771,800.00. Following the transaction, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,894,849.68. This trade represents a 34.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last three months, insiders sold 622,718 shares of company stock valued at $350,859,876. 8.60% of the stock is currently owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.